Loading...
•
Dec 31, 2022
Guardant Health Q4 2022 Earnings Report
Reported an increase in revenue and test volumes, launched new offerings, and expanded market access.
Key Takeaways
Guardant Health reported a 17% increase in revenue for Q4 2022 compared to Q4 2021, driven by growth in clinical and biopharma testing volumes. The company also highlighted advancements in its screening portfolio, including the ECLIPSE study for colorectal cancer detection.
Revenue increased by 17% compared to the fourth quarter of 2021.
Clinical test volume increased by 41% year-over-year.
Biopharma test volume increased by 24% year-over-year.
Demonstrated strong sensitivity and specificity in the ECLIPSE study for colorectal cancer detection with Shield.
Revenue by Segment
Forward Guidance
Guardant Health expects full year 2023 revenue to be in the range of $525 million to $540 million, representing growth of 17% to 20% compared to full year 2022. We expect full year 2023 operating expenses to be below full year 2022, and free cash outflow to be approximately $350 million in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...